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Abstract
Background—The genetic characterization of wild-type measles viruses plays an important role 
in the description of viral transmission pathways and the verification of measles elimination. The 
450 nucleotides that encode the carboxyl-terminus of the nucleoprotein (N-450) are routinely 
sequenced for genotype analysis.
Objectives—The objectives of this study were to develop improved primers and controls for RT-
PCR reactions used for genotyping of measles samples and to develop a method to provide a 
convenient, safe, and inexpensive means to distribute measles RNA for RT-PCR assays and 
practice panels.
Study design—A newly designed, genetically defined synthetic RNA and RNA isolated from 
cells infected with currently circulating genotypes were used to compare the sensitivity of primer 
pairs in RT-PCR and nested PCR. FTA® cards loaded with lysates of measles infected cells were 
tested for their ability to preserve viral RNA and destroy virus infectivity.
Results—A new primer pair, MeV216/MeV214, was able to amplify N-450 from viruses 
representing 10 currently circulating genotypes and a genotype A vaccine strain and demonstrated 
100-fold increased sensitivity compared to the previously used primer set. A nested PCR assay 
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further increased the sensitivity of detection from patient samples. A synthetic positive control 
RNA was developed that produced PCR products that are distinguishable by size from PCR 
products amplified from clinical samples. FTA® cards completely inactivated measles virus and 
stabilized RNA for at least six months.
Conclusions—These improved molecular tools will advance molecular characterization of 
circulating measles viruses globally and provide enhanced quality control measures.
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1. Background
Molecular characterization of MeV has provided a valuable tool for measuring the 
effectiveness of measles control programs [1–3]. The WHO Measles and Rubella Laboratory 
Network (LabNet) supports genetic characterization of circulating wild-type viruses 
throughout the world [2,4]. Genetic characterization of MeVs is based on sequence analysis 
of the 450 nucleotides coding for the 150 amino acids at the carboxyl terminus of the 
nucleoprotein (N-450) [5,6]. Based on these sequences, 24 genotypes have been identified 
[6,7]. Since 1998, the standard genotyping RT-PCR assay from the CDC recommended a 
primer pair designated MV60/MV63.3 [8] though other primers were also used throughout 
LabNet [9–14]. Several new MeV genotypes have been described since the introduction of 
the standard genotyping method [15–17]; however, only limited sequence data were 
available for the primer binding sites of the more recent strains and the analytic sensitivity of 
the primers had not been evaluated. Several laboratories have introduced nested PCR assays, 
some of which do not amplify the complete N-450 [11,18–21] or do not provide data for 
sensitivity and specificity [9,10].
2. Objectives
The first objective was to determine the sensitivity of primers MV60/MV63.3 for viruses 
representing 10 currently circulating genotypes and genotype A and to develop primer pairs 
for RT-PCR and nested PCR that amplify N-450 with increased sensitivity. A second 
objective was to develop reagents for a quality control program for molecular techniques in 
LabNet. This includes a genetically defined positive control RNA, which can be 
differentiated from positive samples. It also includes the development of an RNA test panel 
that could be provided in a convenient, safe and inexpensive format to allow laboratories to 
build competence with the methods for measles genotyping.
3. Study design
3.1. Viruses and cells
Viruses (Table 1) were derived from the WHO Strain Bank at CDC. Vero/hSLAM cells 
(generous gift of Dr. Yanagi) [22] were maintained and infected as described previously 
[23]. To produce viral lysates, infected cells were scraped into cell culture medium and 
stored at −70 °C.
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3.2. RNA extraction, RT-qPCR and sequencing
Total cellular RNA from infected or uninfected cells was isolated using Trizol (Invitrogen) 
and stored at −70 °C. A one-step RT-qPCR was used to determine the copy number of N 
gene-containing RNA (positive and negative strand) as described previously [24]. Synthetic 
MeV N gene RNA was used to establish a standard curve [24]. RNA extracts were diluted to 
defined copy numbers/μL in TE buffer (10 mM Tris–HCl, 1 mM EDTA, pH 7.0). In all 
dilutions, the total RNA concentration was normalized through addition of RNA extracted 
from uninfected cells to a concentration of 4.4 ng/μL. After dilution, RT-qPCR was repeated 
to confirm expected concentrations of N gene-containing RNA. RNA from patient samples 
was extracted using the QIAamp Viral RNA Mini Kit (Qiagen) or the MagNA Pure LC total 
nucleic acid isolation kit (Roche).
For sequence determination, a fragment containing nucleotides 1–3470 of the MeV genome 
was amplified from each RNA preparation. Reverse transcriptase reactions and sequencing 
were performed as described previously [25].
3.3. Genotyping RT-PCR and nested PCR
The Superscript One-step RT-PCR kit with Platinum Taq (Invitrogen) was used for 
genotyping RT-PCR with 2 mM MgSO4, 10 units RNase inhibitor (Applied Biosystems) and 
5 μL sample. The concentration of primers (Table 2) was 0.2 μM. Cycling conditions were 
55 °C for 30 min, 94 °C for 2 min, 40 cycles of 94 °C for 15 s, 55 °C for 30 s, 72 °C for 30 s 
followed by final extension at 72 °C for 7 min. In all template dilutions, except for patient 
samples, the total RNA content was normalized through addition of RNA extracted from 
uninfected cells to a concentration of 4.4 ng/μL. For the nested PCR, Platinum Taq DNA 
Polymerase High Fidelity (Invitrogen) was used according to the manufacturer’s 
recommendations with 0.4 μM primers and 2 μL unpurified RT-PCR product as template. 
Cycling conditions were 94 °C for 30 s, 40 cycles of 94 °C for 15 s, 50 °C for 30 s, 68 °C for 
1 min followed by final extension at 72 °C for 5 min. The sensitivity of RT-PCR combined 
with nested PCR was compared with the method by Kühne et al. [11] using a different assay 
formulation (see Supplementary methods). PCR products were separated on 1% agarose gels 
stained with GelRed (Biotium) and visualized using an imaging system (UVP).
3.4. Synthetic RNA with insert
A plasmid containing the nucleocapsid (N) and phosphoprotein (P) genes of a genotype D3 
virus [26] (accession number EU29350) and a cloned version of the chloramphenicol-acetyl-
transferase gene (pMVplusCAT [27]) were used as templates. An overlapping PCR fragment 
strategy [28,29] was used to amplify nucleotides 533–1521 (genomic numbering) of the N 
gene followed by nucleotides 1109–1328 of pMVplusCAT, followed by nucleotide 1522–
1765 of the N–P gene region. The resulting PCR fragment, MeV-N3in, was inserted into the 
vector pTM1 [30] using restriction sites SacI and SpeI. Sequences of amplification primers 
are available upon request. Identity of the cloned construct was confirmed by sequencing. 
The Megascript T7 and Megaclear kits (Ambion) were used to generate RNA transcripts 
from the plasmid. The concentration of the synthetic RNA transcript was measured 
spectrophotometrically. Dilutions of the transcript were made in TE buffer and stored in 
aliquots at −70 °C.
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3.5. Preparation of FTA® test panels
Indicating FTA® micro cards (Whatman, part number WB120311) with 25 mm diameter 
circles were loaded with 200 μL lysate and dried at RT for 1 h. Disks of 6 mm diameter were 
cut out with a stainless steel puncher (Staples). To avoid cross-contamination, the punch and 
forceps used to handle the filters were cleaned by incubation in 10% bleach for 1 min, rinsed 
with water, then with 70% ethanol for 1 min and air dried between samples. Disks were 
stored at 4 °C sealed in airtight bags with desiccant packs. RNA was extracted from the 
disks using the QIAamp Viral RNA Mini Kit (Qiagen) with the following modifications: 150 
μL PBS and 600 μL AVL buffer were added to each disk, mixed for 15 s, then incubated at 
RT for 10 min. After centrifugation at 15,700 × g for 2 min at RT, 700 μL of the solution 
was transferred to a fresh tube and 560 μL of ethanol were added. The mixture was loaded 
onto a spin column and the purification was completed according to the manufacturer’s 
recommendations.
To measure the viability of measles viruses on FTA® cards, a 6 mm punch was mixed with 
inoculation medium [23], incubated at RT for 10 min and mixed again. The medium 
(without the filter) was used to inoculate Vero/hSLAM cells which were monitored for cpe 
for five days. Cultures without cpe were passaged by trypsinization twice before they were 
determined to be negative.
The genotyping practice panel consisted of four 1.5 mL tubes containing one FTA® disk 
each loaded with a different measles genotype and one tube with a disk loaded with lysate of 
uninfected cells. Kits were transported at RT to participating LabNet members.
4. Results and discussion
4.1. Comparison of primers MV60/MV63.3 with primers MeV216/MeV214
Ten MeVs representing currently circulating genotypes were chosen for analysis (Table 1). 
The Edmonston-wt strain, a representative of genotype A, was included because all vaccine 
strains have been derived from genotype A viruses and thus, are all contained within this 
single genotype [31]. The sequence of 150 nucleotides 5′ of N-450 and of the 3′ noncoding 
region of the N gene (in message sense RNA) were determined. The sequence of the 
Edmonston-wt strain was obtained from GenBank (accession number AF266288). Fig. 1 
shows the sequence variability in the binding sites of MV60, MV63.3 and the reduced 
nucleotide variability in the binding sites of MeV216 and MeV214. The position of MeV214 
increases the distance between the primer binding site and the 3′ terminus of N-450, which 
improves sequence quality. Unlike several previously published primer pairs [11,18–21], the 
new primers allow sequencing of the entire N-450 which is required to assign a genotype 
[32] and to submit the sequence to MeaNS [2], the global measles sequence database. In this 
study, only one representative for each genotype was sequenced. As the variability within 
genotypes can be as high as 5.3% [33], it is possible that other viruses belonging to the same 
genotype may have additional substitutions in the primer binding sites. However the new 
primer set performed very well for routine molecular surveillance for measles in the US (see 
below).
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4.2. Sensitivity and specificity of one-step RT-PCR with MeV216/MeV214
The synthetic RNA (MeV-N3in) comprises nt 533–1764 of the genome of a D3 virus (MVi/
Davis.USA/87), including the entire 3′ non-coding-region of the N gene where the reverse 
primer (MeV214) binding site is located. The synthetic construct contains a 220 nt insertion 
in N-450 (Fig. 2). Serial dilutions of RNA preparations from cells infected with 11 
genotypes and of MeV-N3in were used to determine the sensitivity of the primer pairs. The 
limit of sensitivity for primers MV60/MV63.3 was 106 copies for the 11 genotypes (Fig. 3A) 
and MeV-N3in (Fig. 3B). RT-PCR with 105 copies did not reproducibly amplify all 
genotypes (data not shown). The increased molecular weight of the 854 nt amplicon 
generated from MeV-N3in was clearly distinguishable in a 1% agarose gel from the 634 nt 
amplicon generated from RNA extracted from infected cells (Fig. 3B). This facilitates 
differentiation between amplicons generated from patient samples and from control RNA 
and rules out cross-contamination with control RNA. The limit of sensitivity for primers 
MeV216/MeV214 was 104 copies for the 11 genotypes (Fig. 4A). Amplification from 103 
copies was not reproducibly positive for all genotypes tested (data not shown) but was 
positive for MeV-N3in (Fig. 4B). The difference in sensitivity between the serially diluted 
MeV-N3in and amplifications with all 11 genotypes may be due to slight differences in the 
concentration of RNA in the preparations from different genotypes. MV60/MV63.3 
amplified all 11 genotypes with comparable sensitivity, despite the high number of 
substitutions in primer binding sites. However, primers MeV216/MeV214 demonstrated 
100-fold increased sensitivity. Determining the genotype of each chain of transmission is 
recommended by WHO [34]. Achieving this goal will be facilitated by using an updated 
standard genotyping assay containing primers MeV216/MeV214. Primers MeV216/
MeV214 were used in routine testing of 324 samples submitted to the CDC for domestic 
measles surveillance. Viruses from genotypes A, D4, B3, D8, D9, H1 and G3 were detected 
at concentrations as low as 104 copies per reaction (data not shown).
Primers MeV216/MeV214 were tested with RNA extracted from samples obtained from five 
rubella cases, four mumps cases, one case each of human parainfluenza virus 1 and 4, and 
one case of parvovirus B19 infection. DNA from five different herpes viruses (varicella 
zoster virus, human herpes virus 6B, herpes simplex virus 1, Epstein Barr virus and 
cytomegalovirus) was also tested. All samples had tested positive in assays for the respective 
pathogens. None of the reactions produced amplicons with MeV216/MeV214, 
demonstrating the specificity of the primer pair (data not shown).
Based on the results described above, an MeV genotyping kit was designed to contain 
primers MeV216/MeV214, vacuum-dried MeV-N3in positive control RNA and TE buffer 
for rehydration of the synthetic RNA. The kit is provided to LabNet members upon request.
4.3. Nested PCR
To further increase sensitivity of detection, primers MeV210/MeV217 were designed to 
amplify the DNA fragment generated with MeV216/MeV214 (Table 2). A thermostable 
DNA polymerase with reduced error rate was chosen to decrease the likelihood of 
introduction of polymerase errors. RT-PCR with MeV216/MeV214 followed by nested PCR 
with MeV210/MeV217 amplified 102 copies of serially diluted MeV-N3in RNA and 
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reproducibly amplified 103 copies of all 11 genotypes (Fig. 5A and B). Not all genotypes 
reproducibly amplified when using 102 copies as starting material (data not shown). 
Sequencing of nested PCR products from genotype A produced sequences that were 
identical to the published sequence (AF266288), indicating that no PCR errors were 
detectable in the consensus sequence (data not shown).
Nested PCR was used to amplify N-450 from seven patient samples (four urine samples, two 
nasopharyngeal aspirates and one throat swab). Two of these had previously been genotyped 
using RT-PCR with primers MV60/MV63.3. Sequencing of the nested PCR products 
confirmed the previously obtained sequence, again indicating that no PCR errors were 
detectable in the consensus sequence (data not shown). Of the 5 samples which were 
negative with primers MV60/MV63.3, three were genotyped as D4, D8 and H1, respectively, 
using the nested PCR protocol. In addition, 36 patient samples that had been genotyped 
using the nested PCR assay described by Kühne [11] were amplified with the new nested 
PCR assay to compare the sensitivity of the two assays. The 36 samples containing 
genotypes A, B3, D8, D9, G3 and H1 included three nasopharyngeal aspirates, two throat 
swabs, two cell culture fluids, one throat/nasal swab, one urine sample and 27 sera. Thirty-
five of the samples were positive with the new nested PCR assay, one sample (serum, 
genotype G3) was negative. The assay described by Kühne provides sequence information 
for only 444 of the 450 nt of N-450. The new nested assay demonstrated comparable 
sensitivity while allowing the sequencing of the entire N-450. In addition, the primers 
MeV210/MeV217 demonstrated fewer mismatches with the 11 genotypes than primers 
described in other nested assays [9,10].
4.4. Utility of FTA® cards as practice panels
FTA® cards inactivate infectious material and stabilize nucleic acids [35,36]. FTA® cards 
have been used to transport or store a wide variety of virologic samples which can be 
shipped as non-infectious material at ambient temperatures [37–43]. To test the stability of 
measles RNA stored on FTA® cards, lysates of four genotypes (Table 1) were loaded on 
FTA® cards. RNA extracted from one FTA® disk for each genotype was analyzed by RT-
qPCR. The average Ct of all disks was 17.8 on day 1 and 18.1 after storage at 4 °C for 6 
months (Fig. 6). Storage of FTA® disks at 37 °C for one week did not affect RNA stability 
(data not shown). Lysate eluted from disks was also used to inoculate Vero/hSLAM cells to 
test for virus viability. Repeated virus isolation attempts with two genotypes did not produce 
MeV cpe after three blind passages in cell culture, demonstrating that the FTA® cards had 
inactivated the virus [36,44].
FTA® practice panels consisted of 1.5 mL tubes containing one 6 mm disk loaded with a 
lysate of one of four MeV genotypes and one disk loaded with a lysate of uninfected cells. 
These panels were used in training workshops for 37 laboratories from all 6 WHO regions. 
In most cases, the FTA panels were transported at room temperature. None of the 
laboratories experienced difficulties with recovering RNA from the FTA cards and almost all 
of the laboratories were able to detect all samples by RT-PCR and to correctly identify the 
genotypes. The success of the practice panels demonstrated the utility of FTA® cards as a 
means to ship RNA at ambient temperature. FTA® card panels may be used to develop 
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proficiency panels for LabNet members with PCR and genotyping capacities to ensure 
reliable results from virologic surveillance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Supplementary data associated with this article can be found, in the online version, at http://
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Fig. 1. 
Genetic variability of primer binding sites among 11 genotypes. (A) Schematic 
representation of measles genome and location of N-450. N, P/C/V, M, F, H, L are measles 
genes. (B) Nucleotide sequence of primer binding sites of 11 genotypes. Left side of figure 
depicts forward primer binding sites, right side of figure depicts reverse primer binding sites. 
Dots below the consensus sequence indicate variable positions. Numbers above the 
consensus sequence refer to nucleotide positions in the measles genome.
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Fig. 2. 
Schematic representation of synthetic RNA MeV-N3in. RNA consists of nucleotides 533–
1765 of the measles genome including a 220 nucleotide insert derived from the bacterial 
chloramphenicol-acetyl-transferase gene. The location of the qRT-PCR product and the 
product of genotyping RT-PCR are also indicated.
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Fig. 3. 
RT-PCR with primers MV60/MV63.3. (A) Viral RNA. Lanes 1–11: genotypes as listed in 
Table 1, 106 copies/reaction. (B) MeV-N3in. Lanes 1–6: 10-fold serial dilution of MeV-
N3in, 106–10 copies/reaction. un, RNA from uninfected cells; H2 O, water control.
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Fig. 4. 
RT-PCR with primers MeV216/MeV214. (A) Viral RNA. Lanes 1–11: genotypes as listed in 
Table 1, 104 copies/reaction. (B) MeV-N3in. Lanes 1–6: 10-fold serial dilution of MeV-
N3in, 106–10 copies/reaction. un, RNA from uninfected cells; H2 O, water control.
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Fig. 5. 
Nested PCR with primers MeV210/MeV217. (A) Lanes 1–11: genotypes as listed in Table 
1, 103 copies/reaction. (B) MeV-N3in. Lanes 1–6: 10-fold serial dilution of synthetic RNA, 
106–10 copies/reaction. un, RNA from uninfected cells; H2 O, water control.
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Fig. 6. 
Stability of RNA on FTA® disks. RNA extracted from one FTA® disk loaded with the 
indicated genotype (Table 1) was analyzed by RT-qPCR after incubation at 4 °C for one day 
or six months. Ct values are averages of three replicate wells. Error bars indicate one 
standard deviation.
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Table 1
MeV Isolates used in this study.
Genotype Virus
A MVi/Edmonston-wt.USA/54a,b
B3 MVi/New Jersey.USA/45.05b,c
D2 MVi/NewYork.USA/11.00b
D3 MVi/Illinois.USA/89/1a,b
D4 MVi/New York.USA/14.08/1b
D4 MVi/New York.USA/26.09/3c
D5 MVi/Pennsylvania.USA/34.07b
D6 MVi/St. Petersburg.RUS/16.04/4b
D8 MVi/Vellore.IND/08.05b
D8 MVi/Virginia.USA/15.09c
G2 MVi/Amsterdam.NET/49.97a,b
G3 MVi/Gresik.INO/18.02a,b
H1 MVi/Wisconsin.USA15.08/1b
H1 MVi/Pennsylvania.USA/20.09c
a
Reference strain [6].
bStrain used for primer sensitivity tests.
cStrain used for FTA® practice panel.
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Table 2
Primer sequences.
Name Sequence (5′–3′) Locationa
MV60 GCT ATG CCA TGG GAG TAG GAG TGG 1108–1131
MV63.3 CTG GCC CTC GGC CTC TCG CAC 1686–1706
MeV214 TAA CAA TGA TGG AGG GTA GG 1718–1737
MeV216 TGG AGC TAT GCC ATG GGA GT 1104–1123
MeV210 GCT ATG CCA TGG GAG TRG GAG TGG 1108–1131
MeV217 CAA TGA TGG AGG GTA GG 1718–1734
aNucleotide position in reference to Edmonston-wt (accession number AF266288) genomic sequence.
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